| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment.
|
Anesthesiology
|
2012
|
2.87
|
|
2
|
Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.
|
Pain
|
2006
|
2.71
|
|
3
|
Electrosurgery and implantable electronic devices: review and implications for office-based procedures.
|
Dermatol Surg
|
2011
|
2.07
|
|
4
|
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.
|
J Neurochem
|
2005
|
1.68
|
|
5
|
Symptoms of B12 deficiency can occur in women of child bearing age supplemented with folate.
|
Neurology
|
2002
|
1.63
|
|
6
|
Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review.
|
Acta Oncol
|
2012
|
1.49
|
|
7
|
Premature ovarian aging in mice deficient for Gpr3.
|
Proc Natl Acad Sci U S A
|
2005
|
1.41
|
|
8
|
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
|
Curr Alzheimer Res
|
2012
|
1.41
|
|
9
|
Biochemistry of Tau in Alzheimer's disease and related neurological disorders.
|
Expert Rev Proteomics
|
2008
|
1.21
|
|
10
|
Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer.
|
Cancer Res
|
2010
|
1.13
|
|
11
|
Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord.
|
Anesthesiology
|
2005
|
1.08
|
|
12
|
From tau phosphorylation to tau aggregation: what about neuronal death?
|
Biochem Soc Trans
|
2010
|
1.08
|
|
13
|
The influence of comorbid depression on quality of life for people with epilepsy.
|
Epilepsy Behav
|
2003
|
1.07
|
|
14
|
Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model.
|
J Neurosci
|
2012
|
1.06
|
|
15
|
Invasive palliative interventions: when are they worth it and when are they not?
|
Cancer J
|
2010
|
1.04
|
|
16
|
A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.
|
Neurobiol Dis
|
2009
|
1.04
|
|
17
|
Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin.
|
J Neurosci
|
2003
|
1.04
|
|
18
|
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease.
|
J Biol Chem
|
2006
|
1.03
|
|
19
|
The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy.
|
Epilepsy Behav
|
2004
|
1.00
|
|
20
|
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology.
|
Neurobiol Dis
|
2011
|
1.00
|
|
21
|
The influence of comorbid depression on seizure severity.
|
Epilepsia
|
2003
|
0.99
|
|
22
|
Minocycline in phenotypic models of Huntington's disease.
|
Neurobiol Dis
|
2005
|
0.98
|
|
23
|
Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission.
|
Neurobiol Learn Mem
|
2010
|
0.96
|
|
24
|
Association between caffeine intake and age at onset in Huntington's disease.
|
Neurobiol Dis
|
2013
|
0.94
|
|
25
|
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
|
Prog Neurobiol
|
2007
|
0.94
|
|
26
|
Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study.
|
J Cachexia Sarcopenia Muscle
|
2013
|
0.94
|
|
27
|
Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.
|
Diabetes
|
2012
|
0.93
|
|
28
|
D-β-hydroxybutyrate is protective in mouse models of Huntington's disease.
|
PLoS One
|
2011
|
0.92
|
|
29
|
Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease.
|
Mol Cell Neurosci
|
2007
|
0.91
|
|
30
|
Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.
|
J Pain Symptom Manage
|
2007
|
0.91
|
|
31
|
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.
|
Neuropharmacology
|
2005
|
0.89
|
|
32
|
Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? - analysis from a multicenter cross sectional study.
|
Acta Oncol
|
2013
|
0.88
|
|
33
|
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
|
Epilepsia
|
2015
|
0.88
|
|
34
|
Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
|
Neurobiol Dis
|
2011
|
0.88
|
|
35
|
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.
|
Aging Cell
|
2012
|
0.87
|
|
36
|
Ghrelin-induced hypothermia: a physiological basis but no clinical risk.
|
Physiol Behav
|
2011
|
0.86
|
|
37
|
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
|
J Neuropathol Exp Neurol
|
2007
|
0.86
|
|
38
|
From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
|
Biochem Soc Trans
|
2014
|
0.85
|
|
39
|
Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
|
Epilepsia
|
2014
|
0.85
|
|
40
|
Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
|
Brain Res
|
2010
|
0.84
|
|
41
|
Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring.
|
Clin Nutr
|
2011
|
0.84
|
|
42
|
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms.
|
Neurobiol Dis
|
2004
|
0.83
|
|
43
|
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
|
Curr Pharm Des
|
2008
|
0.82
|
|
44
|
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.
|
J Virol
|
2012
|
0.82
|
|
45
|
Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials.
|
Clin J Pain
|
2009
|
0.82
|
|
46
|
Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease.
|
J Alzheimers Dis
|
2013
|
0.81
|
|
47
|
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
|
Pharmacoepidemiol Drug Saf
|
2008
|
0.81
|
|
48
|
PTU-induced hypothyroidism in rats leads to several early neuropathological signs of Alzheimer's disease in the hippocampus and spatial memory impairments.
|
Hippocampus
|
2014
|
0.81
|
|
49
|
Hippocampal BDNF expression in a tau transgenic mouse model.
|
Curr Alzheimer Res
|
2012
|
0.80
|
|
50
|
Self-report measurement of pain & symptoms in palliative care patients: a comparison of verbal, visual and hand scoring methods in Sub-Saharan Africa.
|
Health Qual Life Outcomes
|
2014
|
0.80
|
|
51
|
Lack of minocycline efficiency in genetic models of Huntington's disease.
|
Neuromolecular Med
|
2007
|
0.80
|
|
52
|
Model-Based Deep Brain Stimulation Programming for Parkinson's Disease: The GUIDE Pilot Study.
|
Stereotact Funct Neurosurg
|
2015
|
0.80
|
|
53
|
Measuring the effects of antiepileptic medications on balance in older people.
|
Epilepsy Res
|
2006
|
0.80
|
|
54
|
A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia.
|
J Pain
|
2009
|
0.79
|
|
55
|
Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor.
|
Transfusion
|
2011
|
0.79
|
|
56
|
A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
|
Neurobiol Dis
|
2010
|
0.79
|
|
57
|
Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.
|
Neurobiol Aging
|
2012
|
0.79
|
|
58
|
Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies.
|
Medscape J Med
|
2008
|
0.79
|
|
59
|
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
|
J Neurol Neurosurg Psychiatry
|
2012
|
0.79
|
|
60
|
Progressive age-related cognitive decline in tau mice.
|
J Alzheimers Dis
|
2013
|
0.79
|
|
61
|
Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease.
|
Curr Alzheimer Res
|
2009
|
0.78
|
|
62
|
Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity?
|
Mov Disord
|
2009
|
0.78
|
|
63
|
Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts.
|
Cell Transplant
|
2008
|
0.78
|
|
64
|
Minocycline-induced activation of tetracycline-responsive promoter.
|
Neurosci Lett
|
2003
|
0.77
|
|
65
|
A randomized, controlled, dose-ranging study investigating single doses of GW406381, naproxen sodium, or placebo in patients with acute pain after third molar tooth extraction.
|
Clin J Pain
|
2009
|
0.77
|
|
66
|
Tau protein: function and pathology.
|
Int J Alzheimers Dis
|
2012
|
0.76
|
|
67
|
Clearance of manganese from the rat substantia nigra following intra-nigral microinjections.
|
Neurosci Lett
|
2002
|
0.76
|
|
68
|
Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia.
|
Behav Brain Res
|
2012
|
0.76
|
|
69
|
Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
|
Neurology
|
2016
|
0.76
|
|
70
|
Citicoline is not protective in experimental models of Huntington's disease.
|
Neurobiol Aging
|
2006
|
0.75
|
|
71
|
A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy.
|
Epilepsy Behav
|
2005
|
0.75
|
|
72
|
Alzheimer's disease risk, obesity and tau: is insulin resistance guilty?
|
Expert Rev Neurother
|
2013
|
0.75
|
|
73
|
Life-threatening hypoglycemia with moxifloxacin in a dialysis patient.
|
J Clin Pharmacol
|
2012
|
0.75
|
|
74
|
A 32-year-old male with recurrent hypothermia and hypotension of unknown cause.
|
Med Princ Pract
|
2012
|
0.75
|
|
75
|
[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?].
|
Therapie
|
2010
|
0.75
|